Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
AVTE Aerovate
22.850-0.840-3.55%
Close
01/31 16:00 ET
22.8500.0000.00%
Post Mkt Price 01/31 16:01 ET
High
24.225
Open
23.760
Turnover
679.87K
Low
22.590
Pre Close
23.690
Volume
29.50K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Press Release: Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical
Contrasting Aerovate Therapeutics (NASDAQ:AVTE) and Concert Pharmaceuticals (NASDAQ:CNCE)
Aerovate Therapeutics (NASDAQ:AVTE – Get Rating) and Concert Pharmaceuticals (NASDAQ:CNCE – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two
Aerovate Therapeutics (NASDAQ:AVTE) Shares Down 6.3%
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Rating) shares dropped 6.3% during trading on Thursday . The stock traded as low as $23.70 and last traded at $23.70. Approximately 2,369 shares traded
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Insider Sells $267,178.32 in Stock
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Rating) insider Benjamin T. Dake sold 10,284 shares of Aerovate Therapeutics stock in a transaction that occurred on Friday, January 6th. The stock was
Ambrx Biopharma, PaxMedica And 3 More Short Squeeze Stocks That Could Soar This Week
Potential short squeeze plays gained steam in 2021 and have continued to attract attention, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the
Aerovate Therapeutics (NASDAQ:AVTE) Trading Down 4.3% Following Insider Selling
Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Rating) traded down 4.3% during mid-day trading on Friday following insider selling activity. The stock traded as low as $25.50 and last trade
Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Sees Significant Growth in Short Interest
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Rating) was the target of a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling
Calculating The Fair Value Of Aerovate Therapeutics, Inc. (NASDAQ:AVTE)
Singing Machine, Blue Apron, Camber Energy And More Short Squeeze Candidates That Could Soar This Week
Potential short squeeze plays gained steam in 2021 and have continued through 2022, with new traders looking for the next huge move. High short interest and a high cost to borrow are among the common
Aerovate Therapeutics (NASDAQ:AVTE) Shares Down 3.3%
Aerovate Therapeutics, Inc. (NASDAQ:AVTE – Get Rating) fell 3.3% during mid-day trading on Tuesday . The stock traded as low as $25.24 and last traded at $25.24. 27 shares traded hands during mid-day
Company Overview
More
Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was founded by Benjamin T. Dake on July 27, 2018 and is headquartered in Waltham, MA.
CEO： Mr. Timothy P. Noyes
Market： NASDAQ
Listing Date： 06/30/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet